查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103853

反義與RNAi療法市場：全球市場預測，2026-2032年

Antisense & RNAi Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，反義和 RNAi 療法市場將成長至 152.3 億美元，複合年成長率為 15.76%。

主要市場統計數據
基準年 2025 54.6億美元
預計年份：2026年 62.5億美元
預測年份 2032 152.3億美元
複合年成長率 (%) 15.76%

反義和RNAi療法執行摘要

反義和RNA干擾（RNAi）療法透過在有害蛋白質產生之前標靶致病RNA，正在變革精準醫療。這類療法包括反義寡核苷酸、小干擾RNA、 微型RNA調變器、剪接轉換寡核苷酸以及其他旨在抑制、分解或修飾基因表現的相關RNA標靶療法。隨著藥物遞送技術的進步、給藥間隔的延長以及對RNA靶向藥物研發監管的日益深入理解，這些療法的臨床意義正擴展到罕見遺傳病、神經病學、心血管疾病、代謝性疾病、腫瘤學、感染疾病和眼科學等領域。該領域的發展正日益依賴檢驗的基因標靶、基於生物標記的患者識別以及遞送平台（例如GalNAc結合、脂質奈米顆粒和組織特異性配體系統）的融合。隨著醫療保健系統優先考慮疾病修正治療，反義和 RNAi 療法正變得越來越重要，因為它們可以解決以前難以用藥物治療的靶點，能夠基於基因組數據進行合理設計，並支持從靶點發現到臨床候選藥物選擇的快速迭代。

RNA標靶療法的變革性變化

隨著業界從第一代RNA標靶藥物轉向更持久、組織選擇性更強、擴充性的平台，反義和RNAi療法領域正經歷著變革。核苷酸化學的進步，包括骨架修飾和糖化學最佳化，提高了藥物的穩定性、效力和耐受性。遞送技術的創新仍然是一項核心挑戰；雖然靶向肝臟的GalNAc綴合物已被臨床驗證可作為肝細胞遞送途徑，但肝外遞送在神經系統疾病、免疫系統疾病、腫瘤、肌肉疾病和呼吸系統疾病等領域仍是一個尚未充分開發的領域。監管預期也在發生變化，更加重視標靶檢驗、脫靶評估、免疫活化風險、生物分佈和長期安全性監測。臨床開發正朝著基因明確的患者群體、早期療育和伴隨生物標記策略的方向發展。同時，生產能力也日趨專業化，需要高純度寡核苷酸合成、可靠的分析表徵、雜質控制以及用於修飾核苷酸和綴合物的穩定供應鏈。這些變化正使反義寡核苷酸療法和RNAi療法成為下一代精準醫療的基礎工具。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善標靶發現、定序、脫靶預測、生物標記選擇和臨床試驗最佳化，對反義和 RNAi 療法的影響日益顯著。 AI 模型可以分析基因組、轉錄組、蛋白質組和表現型資料集，以識別疾病相關的 RNA 標靶並優先篩選具有高生物有效性的候選標靶。在定序方面，機器學習有助於預測 RNA 的可及性、結合親和性、化學修飾模式、免疫刺激基序以及與雜合反應相關的潛在毒性。 AI 也透過整合遺傳變異、表現譜、疾病進展標記和真實世界臨床數據來改善患者分層。在研發營運方面，先進的分析技術可以改善方案設計、終點選擇、研究中心可行性評估和安全性訊號監測。然而，AI 的價值取決於高品質的訓練資料集、透明的模型檢驗、實驗支援的預測以及符合監管標準的文件。在反義和 RNAi 療法中，人工智慧與實驗室檢驗、藥理學專業知識和具有臨床意義的轉化生物標記相結合時最為有效。

主要區域的關鍵見解

反義和RNAi療法的研究結果反映了監管基礎設施、基因組醫學普及程度、臨床試驗網路、報銷途徑和生物製造能力等方面的差異。北美地區憑藉其成熟的罕見疾病計畫、完善的寡核苷酸療法監管途徑、強大的學術轉化研究以及美國和加拿大先進的臨床試驗能力，依然保持著活躍的態勢。歐洲受益於協調的監管審查、跨境罕見疾病網路、孤兒藥框架以及對基因組學和分子醫學的公共投資，儘管在各個醫療保健系統中，定價和報銷評估仍然十分複雜。亞太地區正透過中國、日本、韓國、印度、澳洲和東南亞國協不斷擴大的臨床研究能力、國家層面的基因組舉措、對先進療法的更多投資以及更廣泛地參與RNA藥物研發，而日益成為戰略要地。在拉丁美洲，參與臨床研究和獲得專科醫療服務的機會正在逐步增強，其中巴西和墨西哥作為區域中心，在遺傳疾病診斷、監管現代化和先進療法的引入方面發揮關鍵作用。在中東，精準醫療舉措、基因組篩檢計畫以及專科醫院基礎設施的建設正在推動相關領域的發展，尤其是在高所得的海灣國家，針對遺傳和代謝疾病的計畫正在滿足對分子標靶療法的需求。非洲在RNA標靶療法的普及方面仍處於起步階段，但透過擴大基因組監測、建立感染疾病研究網路、提升分子診斷能力以及開展與區域疾病控制重點相符的臨床研究舉措，非洲在RNA標靶療法領域仍具有重要的長期意義。

全球及聯盟範圍內的關鍵群體分析

集團層面的趨勢揭示了政策協調、資金優先事項和醫療基礎設施如何影響反義寡核苷酸和RNAi療法的引入。七國集團（G7）擁有強大的生物醫學研究生態系統、先進的監管科學、成熟的智慧財產權框架以及高水準的專業醫療網路，這些網路支持早期臨床開發、罕見疾病診斷、藥物安全監測和上市後證據生成。歐盟（EU）提供統一的法律規範、罕見疾病框架、共享的健康數據以及與RNA標靶療法相關的多國研究項目，但成員國的報銷決策仍然影響患者的用藥機會。金磚國家（BRICS）由於其龐大的患者群體、不斷擴大的臨床試驗參與度、不斷提升的生物技術能力、國家藥物政策優先事項以及對基因組學和精準醫學的投入增加，正變得日益重要。東協正透過臨床研究體系的發展、分子診斷的擴展、數位醫療的普及和醫療現代化，崛起為一個值得關注的地區，但成員國之間獲得先進基因療法的機會存在顯著差異。海灣合作理事會（GCC）國家優先發展基因組醫學、國家篩檢計畫、三級醫療專科化和當地醫療基礎設施，為精準治療遺傳性疾病、代謝性疾病、心血管疾病和罕見疾病創造了機會。北約成員國擁有眾多先進的生物醫學研究系統和國防相關的生物安全基礎設施，這激發了它們對RNA技術在公共衛生應急準備、快速反應平台、安全供應鏈和韌性醫療能力方面的濃厚興趣。

主要市場的關鍵國別洞察

逐國分析顯示，反義和RNAi療法的全球基礎呈現異質性但不斷擴大的趨勢。美國擁有高度發展的RNA標靶藥物研發現狀系統，涵蓋罕見疾病臨床研究、與監管機構的合作、透過專科藥房進行分銷以及基因組醫學的引入。加拿大透過強大的學術研究、公共資助的醫療保健基礎設施、罕見疾病政策制定以及參與國際臨床研究做出貢獻。墨西哥正在加強參與臨床試驗、分子診斷的普及以及專科醫療途徑的建設，而巴西仍然是拉丁美洲生物醫學研究、監管現代化、公共部門專科醫療以及先進療法引入的領先中心。在歐洲，英國在基因組學、臨床研究基礎設施、健康數據資源和轉化醫學方面實力雄厚，而德國在生物製造、分子診斷、專科醫療和應用生物醫學研究方面佔據重要地位。法國支持罕見疾病網路、國家級生物醫學研究計畫以及以公共衛生主導的創新。義大利和西班牙則透過其臨床研究能力、專科醫院和公共衛生系統做出貢獻。俄羅斯在分子生物學和遺傳學領域擁有強大的科學研究實力，但國際合作、物資供應以及臨床開發條件可能受到地緣政治限制。在亞太地區，中國正迅速拓展其RNA藥物研發、臨床開發能力、基因組學基礎設施和在地化生產。印度擁有強大的藥物生產能力​​、不斷擴展的基因組學計畫、臨床試驗能力以及遺傳多樣性豐富的大規模人口。日本擁有先進的監管流程、對老齡化社會研究的重視、高品質的臨床基礎設施以及精準醫療的引入。韓國正在投資生物技術、RNA平台、數位醫療和精準醫療。澳洲也支持高效的監管流程，以促進全球協調的臨床試驗、基因組學研究、早期生物技術開發和創新藥物的研發。

為行業領導者提供的實用建議

產業領導者應優先考慮檢驗的基因和轉錄組靶點，這些靶點應具有明確的疾病生物學特徵、可測量的生物標記和具有臨床意義的終點。對遞送技術創新的投資至關重要，尤其對於肝外組織，例如中樞神經系統、肌肉、肺臟、免疫細胞和腫瘤。研發團隊應將人工智慧驅動的定序與嚴格的實驗檢驗相結合，以降低脫靶風險並提高候選化合物的品質。生產領導者必須提升寡核苷酸合成能力、雜質分析能力、原料穩定性以及可擴展的結合工作流程。臨床策略應強調招募基因明確的受試者、真實世界數據（REW）規劃、長期安全性監測以及與監管機構和衛生技術評估機構的早期對話。與診斷開發公司、學術基因組研究中心、專科診所和患者權益組織建立合作關係，有助於臨床試驗的選擇和患者參與。此外，各機構應制定能夠解決罕見疾病領域證據不足、價值證明有限、治療永續性不足以及醫療系統預算限制等問題的准入策略，而不是僅依賴傳統的藥物經濟模型。

調查方法

本執行摘要是根據反義寡核苷酸和RNA干擾療法相關科學文獻、監管指南、臨床開發趨勢、公共衛生數據、政策文件和同行評審研究結果的檢驗二手研究和分析。調查方法強調對監管出版刊物、臨床試驗註冊庫、生物醫學資料庫、基因組醫學舉措、藥理學研究和醫療保健政策資訊來源進行三角檢驗。採用質性評估方法評估技術成熟度、遞送平台、治療應用、區域部署準備、臨床開發要求和部署促進因素。特別關注已檢驗的作用機制、安全性考量、生物標記整合、生產複雜性、分析控制和區域醫療保健基礎設施。本分析不涉及市場規模、市場佔有率或預測；而是著重於影響反義寡核苷酸和RNAi療法未來發展的策略、科學、監管和營運因素。

結論

反義寡核苷酸和RNA干擾療法正從專門的基因療法發展成為更廣泛的精準醫療平台，能夠應對以往難以治療的複雜疾病標靶。化學、遞送、診斷、監管科學和人工智慧驅動設計方面的進步正在加強該領域的臨床和營運基礎。區域和國家層面的推廣應用將取決於基因組檢測的可及性、進行臨床試驗的準備、保險報銷機制、生產能力以及醫生對RNA標靶治療模式的理解。最成功的相關人員將結合嚴格的生物學檢驗、差異化的遞送技術、可靠的安全性評估、可擴展的生產結構以及符合患者需求和醫療保健系統要求的循證策略。隨著科學和臨床能力的成熟，反義寡核苷酸療法、 RNA干擾療法和其他RNA標靶藥物有望繼續成為下一代藥物研發的關鍵支柱。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 反義與RNAi治療市場：依寡核苷酸類型分類

  • 反義寡核苷酸
  • 干擾RNA
    • 微干擾RNA
    • 小干擾RNA

第8章 反義與RNAi療法市場：依給藥法分類

  • 鞘內給藥
  • 靜脈
  • 口服
  • 皮下
  • 外用

第9章：反義與RNAi治療市場：依治療領域分類

  • 心血管系統
  • 免疫學
  • 代謝性疾病
  • 神經病變
  • 腫瘤學
  • 眼科
  • 罕見疾病

第10章：反義和RNAi治療市場：依最終用戶分類

  • 受託研究機構
  • 製藥公司
  • 研究所

第11章 反義與RNAi療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 反義與RNAi治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 反義與RNAi療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Acuitas Therapeutics Inc.
  • Alloy Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Benitec Biopharma Limited
  • City Therapeutics
  • Danaher Corporation
  • Eli Lilly and Company
  • Evox Therapeutics Ltd
  • GenScript Biotech Corporation
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Ribocure Pharmaceuticals AB
  • Sanofi SA
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Stoke Therapeutics, Inc.
  • Suzhou Ribo Life Science Co., Ltd.
  • Wave Life Sciences Ltd
Product Code: MRR-8E22B61932A7

The Antisense & RNAi Therapeutics Market is projected to grow by USD 15.23 billion at a CAGR of 15.76% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.46 billion
Estimated Year [2026] USD 6.25 billion
Forecast Year [2032] USD 15.23 billion
CAGR (%) 15.76%

Antisense & RNAi Therapeutics Executive Summary

Antisense and RNA interference (RNAi) therapeutics are reshaping precision medicine by targeting disease-causing RNA before harmful proteins are produced. This therapeutic class includes antisense oligonucleotides, small interfering RNA, microRNA modulators, splice-switching oligonucleotides, and related RNA-targeted modalities designed to silence, degrade, or modify gene expression. Their clinical relevance has expanded across rare genetic disorders, neurology, cardiovascular disease, metabolic disorders, oncology, infectious disease, and ophthalmology, supported by improved delivery chemistry, longer dosing intervals, and growing regulatory familiarity with RNA-targeted drug development. The field is increasingly defined by the convergence of validated genetic targets, biomarker-driven patient identification, and delivery platforms such as GalNAc conjugation, lipid nanoparticles, and tissue-specific ligand systems. As healthcare systems prioritize disease-modifying therapies, antisense and RNAi therapeutics are gaining strategic importance because they can address previously undruggable targets, enable rational design from genomic data, and support faster iteration from target discovery to clinical candidate selection.

Transformative Shifts in RNA-Targeted Therapeutics

The antisense and RNAi therapeutics landscape is undergoing transformative change as the industry moves from first-generation RNA-targeted medicines toward more durable, tissue-selective, and scalable platforms. Advances in nucleotide chemistry, including backbone modification and sugar chemistry optimization, have improved stability, potency, and tolerability. Delivery innovation remains central, with liver-targeted GalNAc conjugates establishing a clinically validated pathway for hepatocyte delivery, while extrahepatic delivery remains a critical frontier for neurology, immunology, oncology, muscle disease, and pulmonary indications. Regulatory expectations are also evolving, with greater emphasis on target validation, off-target assessment, immune activation risk, biodistribution, and long-term safety monitoring. Clinical development is shifting toward genetically defined populations, earlier intervention, and companion biomarker strategies. At the same time, manufacturing capabilities are becoming more specialized, requiring high-purity oligonucleotide synthesis, robust analytical characterization, impurity control, and resilient supply chains for modified nucleotides and conjugation components. These shifts are positioning antisense oligonucleotide therapies and RNAi therapeutics as foundational tools in next-generation precision therapeutics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing antisense and RNAi therapeutics by improving target discovery, sequence design, off-target prediction, biomarker selection, and clinical trial optimization. AI-enabled models can analyze genomic, transcriptomic, proteomic, and phenotypic datasets to identify disease-associated RNA targets and prioritize candidates with stronger biological plausibility. In sequence engineering, machine learning supports prediction of RNA accessibility, binding affinity, chemical modification patterns, immunostimulatory motifs, and potential hybridization-related toxicity. AI also enhances patient stratification by integrating genetic variants, expression signatures, disease progression markers, and real-world clinical data. In development operations, advanced analytics can improve protocol design, endpoint selection, site feasibility, and safety signal monitoring. However, the value of AI depends on high-quality training datasets, transparent model validation, experimentally confirmed predictions, and regulatory-grade documentation. For antisense and RNAi therapeutics, AI is most impactful when paired with wet-lab validation, pharmacology expertise, and clinically meaningful translational biomarkers.

Key Regional Insights Across Major Geographies

Regional development in antisense and RNAi therapeutics reflects differences in regulatory infrastructure, genomic medicine adoption, clinical trial networks, reimbursement pathways, and biomanufacturing capacity. North America remains highly active due to mature rare disease programs, established regulatory pathways for oligonucleotide therapeutics, strong academic translational research, and advanced clinical trial capabilities across the United States and Canada. Europe benefits from coordinated regulatory review, cross-border rare disease networks, orphan medicine frameworks, and public investment in genomic and molecular medicine, although pricing and reimbursement assessment remains complex across individual health systems. Asia-Pacific is gaining strategic relevance through expanding clinical research capacity, national genomics initiatives, increasing investment in advanced therapeutics, and growing participation in RNA medicine development across China, Japan, South Korea, India, Australia, and ASEAN economies. Latin America is progressively strengthening clinical research participation and specialty care access, with Brazil and Mexico serving as important regional anchors for genetic disease diagnosis, regulatory modernization, and advanced therapy adoption. The Middle East is building momentum through precision medicine initiatives, genomic screening programs, and specialty hospital infrastructure, particularly in high-income Gulf economies where inherited and metabolic disorder programs support demand for molecularly targeted therapies. Africa remains at an earlier stage for RNA-targeted therapeutic access but has significant long-term relevance due to expanding genomic surveillance, infectious disease research networks, molecular diagnostics capacity-building, and clinical research initiatives aligned with regional disease priorities.

Key Group Insights Across Global Alliances

Group-level dynamics show how policy coordination, funding priorities, and healthcare infrastructure shape antisense and RNAi therapeutics adoption. G7 countries have strong biomedical research ecosystems, advanced regulatory science, mature intellectual property frameworks, and high-capacity specialty care networks that support early clinical development, rare disease diagnosis, pharmacovigilance, and post-approval evidence generation. The European Union provides harmonized regulatory structures, rare disease frameworks, health data collaboration, and multinational research programs relevant for RNA-targeted therapeutics, although member-state reimbursement decisions still influence patient access. BRICS economies are increasingly important because of their large patient populations, expanding clinical trial participation, growing biotechnology capabilities, domestic pharmaceutical policy priorities, and increasing investment in genomics and precision medicine. ASEAN is emerging as a region of interest through improving clinical research readiness, expanding molecular diagnostics, digital health adoption, and healthcare modernization, although access to advanced genetic medicines varies widely across member states. GCC countries are prioritizing genomic medicine, national screening initiatives, tertiary care specialization, and local healthcare infrastructure development, creating opportunities for precision therapeutics in inherited, metabolic, cardiovascular, and rare disorders. NATO countries collectively include many advanced biomedical research systems and defense-related biosecurity infrastructures, supporting interest in RNA technologies for public health preparedness, rapid-response platforms, secure supply chains, and resilient medical countermeasure capabilities.

Key Country Insights Across Leading Markets

Country-level insights highlight the uneven but expanding global foundation for antisense and RNAi therapeutics. The United States has a highly developed ecosystem for RNA-targeted drug discovery, rare disease clinical research, regulatory engagement, specialty pharmacy distribution, and genomic medicine adoption. Canada contributes through strong academic research, publicly funded healthcare infrastructure, rare disease policy development, and participation in international clinical studies. Mexico is strengthening clinical trial participation, molecular diagnostics access, and specialty medicine pathways, while Brazil remains a leading Latin American hub for biomedical research, regulatory modernization, public-sector specialty care, and advanced therapy adoption. In Europe, the United Kingdom maintains strength in genomics, clinical research infrastructure, health data resources, and translational medicine; Germany is prominent in biomanufacturing, molecular diagnostics, specialist care, and applied biomedical research; France supports rare disease networks, national biomedical research programs, and public health-led innovation; Italy and Spain contribute through clinical research capacity, specialist hospitals, and public health systems; and Russia has scientific capabilities in molecular biology and genetics, though international collaboration, supply access, and clinical development conditions can be affected by geopolitical constraints. In Asia-Pacific, China is rapidly expanding RNA medicine research, clinical development capacity, genomics infrastructure, and local manufacturing; India offers strong pharmaceutical manufacturing capabilities, growing genomics programs, clinical trial capacity, and a large genetically diverse population; Japan provides advanced regulatory pathways, aging-population research relevance, high-quality clinical infrastructure, and precision medicine adoption; South Korea is investing in biotechnology, RNA platforms, digital health, and precision medicine; and Australia supports globally connected clinical trials, genomics research, early-stage biotechnology development, and efficient regulatory pathways for innovative medicines.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated genetic and transcriptomic targets with clear disease biology, measurable biomarkers, and clinically meaningful endpoints. Investment in delivery innovation is essential, particularly for extrahepatic tissues such as the central nervous system, muscle, lung, immune cells, and tumors. Development teams should integrate AI-enabled sequence design with rigorous experimental validation to reduce off-target risk and improve candidate quality. Manufacturing leaders must strengthen oligonucleotide synthesis capacity, impurity analytics, raw material security, and scalable conjugation workflows. Clinical strategy should emphasize genetically defined enrollment, real-world evidence planning, long-term safety monitoring, and early dialogue with regulators and health technology assessment bodies. Partnerships with diagnostic developers, academic genomics centers, specialty clinics, and patient organizations can improve trial identification and patient engagement. Organizations should also prepare access strategies that address rare disease evidence limitations, value demonstration, dosing durability, and healthcare system budget considerations without relying solely on traditional pharmacoeconomic models.

Research Methodology

This executive summary is developed from verified secondary research and evidence-based analysis of scientific literature, regulatory guidance, clinical development trends, public health data, policy documents, and peer-reviewed insights related to antisense oligonucleotides and RNA interference therapeutics. The methodology emphasizes triangulation across regulatory publications, clinical trial registries, biomedical databases, genomic medicine initiatives, pharmacology research, and healthcare policy sources. Qualitative assessment was applied to evaluate technological maturity, delivery platforms, therapeutic applications, regional readiness, clinical development requirements, and adoption enablers. Particular attention was given to validated mechanisms of action, safety considerations, biomarker integration, manufacturing complexity, analytical controls, and regional healthcare infrastructure. The analysis avoids market sizing, market share, and forecasting and instead focuses on strategic, scientific, regulatory, and operational factors that shape the trajectory of antisense and RNAi therapeutics.

Conclusion

Antisense and RNAi therapeutics are advancing from specialized genetic medicines toward a broader precision medicine platform capable of addressing complex, previously inaccessible disease targets. Progress in chemistry, delivery, diagnostics, regulatory science, and AI-assisted design is strengthening the clinical and operational foundation of the field. Regional and country-level adoption will depend on genomic testing access, clinical trial readiness, reimbursement pathways, manufacturing resilience, and physician familiarity with RNA-targeted treatment models. The most successful stakeholders will combine deep biological validation with differentiated delivery technologies, robust safety evaluation, scalable manufacturing, and evidence strategies aligned with patient needs and healthcare system requirements. As scientific and clinical capabilities mature, antisense oligonucleotide therapies, RNA interference therapeutics, and other RNA-targeted medicines are positioned to remain critical pillars of next-generation drug development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type

  • 7.1. Introduction
  • 7.2. Antisense Oligonucleotides
  • 7.3. Interfering RNAi
    • 7.3.1. Micro Interfering RNAs
    • 7.3.2. Small Interfering RNAs

8. Antisense & RNAi Therapeutics Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Intrathecal
  • 8.3. Intravenous
  • 8.4. Oral
  • 8.5. Subcutaneous
  • 8.6. Topical

9. Antisense & RNAi Therapeutics Market, by Therapeutic Areas

  • 9.1. Introduction
  • 9.2. Cardiovascular
  • 9.3. Immunology
  • 9.4. Metabolic Disorders
  • 9.5. Neurological Disorders
  • 9.6. Oncology
  • 9.7. Ophthalmology
  • 9.8. Rare Diseases

10. Antisense & RNAi Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Laboratories

11. Antisense & RNAi Therapeutics Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Antisense & RNAi Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Antisense & RNAi Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Acuitas Therapeutics Inc.
  • 15.2. Alloy Therapeutics, Inc.
  • 15.3. Alnylam Pharmaceuticals, Inc.
  • 15.4. Arbutus Biopharma Corporation
  • 15.5. Arrowhead Pharmaceuticals, Inc.
  • 15.6. AstraZeneca plc
  • 15.7. Bayer AG
  • 15.8. Benitec Biopharma Limited
  • 15.9. City Therapeutics
  • 15.10. Danaher Corporation
  • 15.11. Eli Lilly and Company
  • 15.12. Evox Therapeutics Ltd
  • 15.13. GenScript Biotech Corporation
  • 15.14. GSK PLC
  • 15.15. Ionis Pharmaceuticals, Inc.
  • 15.16. Merck KGaA
  • 15.17. Novo Nordisk A/S
  • 15.18. Pfizer Inc.
  • 15.19. Ribocure Pharmaceuticals AB
  • 15.20. Sanofi S.A.
  • 15.21. Shanghai Argo Biopharmaceutical Co., Ltd.
  • 15.22. Silence Therapeutics plc
  • 15.23. Stoke Therapeutics, Inc.
  • 15.24. Suzhou Ribo Life Science Co., Ltd.
  • 15.25. Wave Life Sciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTISENSE OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTERFERING RNAI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTERFERING RNAI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTERFERING RNAI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICRO INTERFERING RNAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICRO INTERFERING RNAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICRO INTERFERING RNAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMALL INTERFERING RNAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMALL INTERFERING RNAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMALL INTERFERING RNAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 148. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 150. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 154. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 156. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 160. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 162. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 172. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 174. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 178. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 180. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 184. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 186. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 190. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 192. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 196. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 198. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 208. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 210. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 214. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 216. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 220. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 222. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 226. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 228. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 230. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025